The notices it replaced
Its page names no earlier notice: it is new, or it does not say.
Replaced by PAR-18-317.
Who won it before
11 competing awards (new and renewals) from FY2014 to FY2025 under this notice and the notices it replaced: $2,725,357 in first-year total cost, median $211,875.
Most frequent study sections
- Special Emphasis Panel[ZCA1 TCRB-T (O1)]5
- Special Emphasis Panel[ZCA1 RPRB-B (O1)]2
- Special Emphasis Panel[ZCA1 TCRB-Q (J3)]2
- Special Emphasis Panel[ZCA1 TCRB-Q (J2)]1
- Special Emphasis Panel[ZCA1 TCRB-T (M1)]1
Most frequent institutions
- OHIO STATE UNIVERSITY2
- CASE WESTERN RESERVE UNIVERSITY1
- H. LEE MOFFITT CANCER CTR & RES INST1
- MASSACHUSETTS GENERAL HOSPITAL1
- MAYO CLINIC ARIZONA1
| FY | Project | PIs | Institution | First-year cost | Study section |
|---|---|---|---|---|---|
| 2018 | Colorectal Cancer Molecular Subtype Assay Development and Validation1UH2CA207101-01A1 | KOPETZ, SCOTTLUTHRA, RAJYALAKSHMIMARU, DIPEN M.MORRIS, JEFFREY S | UNIVERSITY OF TX MD ANDERSON CAN CTR, TX | $214,027 | ZCA1 |
| 2018 | Clinical development of a blood based assay that detects the BRAF V600E mutation in melanoma and thyroid cancer patients1UH2CA207355-01A1 | SULLIVAN, RYAN J | MASSACHUSETTS GENERAL HOSPITAL, MA | $140,135 | ZCA1 |
| 2017 | Detection of microsatellite instability biomarkers for therapeutic clinical trial eligibility1UH2CA216432-01 | ROYCHOWDHURY, SAMEEK | OHIO STATE UNIVERSITY, OH | $354,168 | ZCA1 |
| 2017 | Molecular diagnostic and prognostic signatures for PTCL1UH2CA206127-01A1 | CHAN, WING C.IQBAL, JAVEED | UNIVERSITY OF NEBRASKA MEDICAL CENTER, NE | $205,470 | ZCA1 |
| 2017 | Development of Mantle Cell Lymphoma Proliferation Signature Assay1UH2CA217847-01 | RIMSZA, LISA | MAYO CLINIC ARIZONA, AZ | $198,578 | ZCA1 |
| 2017 | Advancing EFIRM-Liquid Biopsy (eLB) to a CLIA-Certified Laboratory Developed Test (eLB-LDT) for Detection of Actionable EGFR Mutations in NSCLC Patients1UH2CA206126-01A1 | CHIA, DAVID S.DAS, KINGSHUKSOO HOO, GUYWEI, FANGWONG, DAVID T | UNIVERSITY OF CALIFORNIA LOS ANGELES, CA | $184,223 | ZCA1 |
| 2017 | Optimizing an assay for high risk HPV DNA in body fluids1UH2CA211396-01 | CALIFANO, JOSEPH A | UNIVERSITY OF CALIFORNIA, SAN DIEGO, CA | $128,218 | ZCA1 |
| 2016 | Validation of EGFR Protein Complexes as Molecular Diagnostics1UH2CA202970-01 | HAURA, ERIC B. | H. LEE MOFFITT CANCER CTR & RES INST, FL | $390,763 | ZCA1 |
| 2016 | Assay Validation of Targeted RNA sequencing to Detect Kinase Gene Fusions1UH2CA202971-01 | ROYCHOWDHURY, SAMEEK | OHIO STATE UNIVERSITY, OH | $351,505 | ZCA1 |
| 2016 | Validation of Methylated Vimentin as a Diagnostic Test for Barrett's Esophagus1UH2CA205105-01 | WILLIS, JOSEPH EDWARD | CASE WESTERN RESERVE UNIVERSITY, OH | $346,395 | ZCA1 |
| 2016 | Validation of circulating tumor DNA assays for detection of metastatic melanoma1UH2CA206124-01 | POLSKY, DAVID | NEW YORK UNIVERSITY SCHOOL OF MEDICINE, NY | $211,875 | ZCA1 |
Data: Grants.gov's daily extract and NIH's notice pages and award files, in ScienceGraph release conductgrants-2026-11-10-0.1.1. An award is listed only where NIH's own record names the notice, and a PI only by NIH's profile ID. Grants.gov and NIH do not endorse ScienceDex.